Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q3 2026Earnings call Sep 1, 2026 · most recent call
MDT’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Medtronic’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: MDT daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
On September 14, 2026, Medtronic commenced an offer to exchange up to 225,361,295 newly issued shares of common stock of MiniMed Group, Inc. for outstanding Medtronic ordinary shares, pursuant to a prospectus dated September 14, 2026 included in MiniMed's Form S-4 registration statement. The exchange offer advances the previously announced separation of the MiniMed diabetes business into an independent company.
What each event means for MDT’s sentiment score is part of Tellvest Pro.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q2 | $8.40B | +5.2% | $0.99 | +45.6% | 64.9% | 19.0% | 15.1% | $554M |
| FY2025 Q3 | $8.29B | +2.5% | $1.01 | +2.0% | 66.5% | 19.9% | 15.6% | $2.10B |
| FY2025 Q4 | $8.93B | +3.9% | $0.82 | +67.3% | 64.7% | 16.1% | 11.8% | $2.07B |
| FY2026 Q1 | $8.58B | +8.4% | $0.81 | +1.3% | 57.7% | 16.8% | 12.1% | $584M |
| FY2026 Q2 | $8.96B | +6.6% | $1.07 | +8.1% | 60.3% | 18.8% | 15.3% | $457M |
| FY2026 Q3 | $9.02B | +8.8% | $0.89 | -11.9% | 64.9% | 19.7% | 12.7% | $2.30B |
| FY2026 Q4 | $9.81B | +9.9% | $0.96 | +17.1% | 75.9% | 19.1% | 12.7% | $2.08B |
| FY2027 Q1Selected | $9.76B | +13.7% | $1.14 | +40.7% | 65.0% | 18.1% | 15.1% | $1.29B |
Management-stated figures from MDT’s newest call are part of Tellvest Pro.